StreetInsider.com News Articles

Bicara Therapeutics (BCAX) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:21:05 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight ratingon Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "Multiple good options coming to patients with head & neck cancers. Our consultant specializes in treating SCCHN and indicated that all three bispecifics in Phase 3 development (BCAX’s ficerafusp, GMAB’s [NC] petosemtamab, and JNJ’s amivantamab) are likely to be approved and adopted. In his view, there is value in simply recreating cetuximab’s wellestablished anti-EGFR benefits in a dossier eligible for approval, but he thinks all three drugs go above and beyond that in terms of their efficacy. He does not believe any of the

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Mon, 01 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260601/26583428.html

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Mon, 01 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260601/26583428.html

Bicara Therapeutics (BCAX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 27 May 2026 07:29:08 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "We hosted the Bicara senior management team (CEO, President, CMO, CCO, and VP of IR) for an investor lunch in New York today. Our meeting was hot on the heels of the latest clinical update on ficerafusp (EGFR x TGF-β BsAb) in patients with 1L HPV-negative HNSCC. BCAX shares are up 34% YTD (vs. +10% for the XBI), outperformance that we believe reflects investor appreciation for consistency of data generated by ficerafusp and greater optimism for its competitive positioning relative to GMAB’s (NC)

Form 4 Bicara Therapeutics Inc. For: May 21 Filed by: Hyep Ivan

Tue, 26 May 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26551520.html

Form 4 Bicara Therapeutics Inc. For: May 21 Filed by: Hyep Ivan

Tue, 26 May 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26551520.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Tue, 26 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26549732.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Tue, 26 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26549732.html

Form 8-K Bicara Therapeutics Inc. For: May 21

Thu, 21 May 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260521/26536668.html

Form 8-K Bicara Therapeutics Inc. For: May 21

Thu, 21 May 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260521/26536668.html

Bicara reports three-year survival data for cancer drug combo

Thu, 21 May 2026 17:01:18 -0400

Bicara Therapeutics Inc. (NASDAQ: BCAX) announced extended follow-up data from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma.

The three-year data showed that patients receiving 1500mg weekly of ficerafusp alfa with pembrolizumab had an estimated 31% overall survival rate. The company stated this approximately doubled survival rates compared to a retrospective analysis of standard care treatment with pembrolizumab alone in HPV-negative patients.

The study included approximately 90 patients across three dose groups: 750mg weekly, 1500mg weekly, and 2000mg every other week. Complete response rates increased across all cohorts, reaching

Bicara reports three-year survival data for cancer drug combo

Thu, 21 May 2026 17:01:18 -0400

The study included approximately 90 patients across three dose groups: 750mg weekly, 1500mg weekly, and 2000mg every other week. Complete response rates increased across all cohorts, reaching

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Thu, 21 May 2026 17:00:00 -0400

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals

Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely

Form 144 Bicara Therapeutics Inc. Filed by: Hyep Ivan

Thu, 21 May 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260521/26535051.html